Режимы назначения ингибиторов ангиогенеза при лечении пациентов с неоваскулярной возрастной макулярной дегенерацией
- Авторы: Астахов Ю.С.1, Нечипоренко П.А.1
-
Учреждения:
- ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России
- Выпуск: Том 12, № 2 (2019)
- Страницы: 47-56
- Раздел: Обзоры
- URL: https://journals.rcsi.science/ov/article/view/12625
- DOI: https://doi.org/10.17816/OV2019247-56
- ID: 12625
Цитировать
Аннотация
Данный обзор литературы посвящён сравнению различных режимов назначения ингибиторов ангиогенеза при лечении пациентов с неоваскулярной возрастной макулярной дегенерацией. Описаны подходы к назначению повторных интравитреальных инъекций ингибиторов ангиогенеза, представлены результаты исследований эффективности различных препаратов, применявшихся в разных режимах дозирования, а также перечислены сильные и слабые стороны каждого из рассматриваемых режимов лечения.
Полный текст
Открыть статью на сайте журналаОб авторах
Юрий Сергеевич Астахов
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России
Email: astakhov73@mail.ru
SPIN-код: 7164-4749
Scopus Author ID: 100400235000040023500
ResearcherId: p-1322-2017
д-р мед. наук, профессор, кафедра офтальмологии с клиникой
Россия, Санкт-ПетербургПавел Андеевич Нечипоренко
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России
Автор, ответственный за переписку.
Email: paul_because@mail.ru
ORCID iD: 0000-0002-1604-2569
SPIN-код: 5284-7182
канд. мед. наук, ассистент, кафедра офтальмологии с клиникой
Россия, Санкт-ПетербургСписок литературы
- World Health Organization. Vision 2020. Global initiative for the elimination of avoidable blindness. Geneva: WHO; 2007.
- Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185. https://doi.org/10.1007/s10456-011-9249-6.
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481.
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. https://doi.org/10.1056/NEJMoa062655.
- Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220-226. https://doi.org/10.1136/bjophthalmol-2014-305327.
- Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):647-655. https://doi.org/10.1007/s00417-013-2562-6.
- Mitchel P, Ziemssen F, Scheidow T, et al. Visual acuity outcomes in patients with diabetic macular edema treated with ranibizumab in real-life setting: Results from the final analysis of the LUMINOUS study. In: Proceedings of the 17th EURETINA Congress; 2017 Sep 9; Barcelona, Spain.
- Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248. https://doi.org/10.1016/j.ajo.2007.10.004.
- Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmo¬logy. 2011;118(5):831-839. https://doi.org/10.1016/j.ophtha.2010.09.004.
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548. https://doi.org/10.1016/j.ophtha.2012.09.006.
- Talks JS, Lotery AJ, Ghanchi F, et al. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology. 2016;123(2):337-343. https://doi.org/10.1016/j.ophtha.2015.09.039.
- Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting. Am J Ophthalmol. 2017;174:160-168. https://doi.org/10.1016/j.ajo.2016.09.038.
- Framme C, Eter N, Hamacher T, et al. Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS. Ophthalmol Retina. 2018;2(6):539-549. https://doi.org/10.1016/j.oret.2017.09.017.
- Almuhtaseb H, Kanavati S, Rufai SR, Lotery AJ. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye (Lond). 2017;31(6):878-883. https://doi.org/10.1038/eye.2017.6.
- Epstein D, Amren U. Near Vision Outcome in Patients with Age-Related Macular Degeneration Treated with Aflibercept. Retina. 2016;36(9):1773-7. https://doi.org/10.1097/IAE.0000000000000978.
- Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58 e41. https://doi.org/10.1016/j.ajo.2009.01.024.
- Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4): 663-71. https://doi.org/10.1016/j.ophtha.2010.12.019.
- Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731-1739. https://doi.org/10.1016/j.ophtha.2009.05.024.
- Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175-83. https://doi.org/10.1016/j.ophtha.2011.12.016.
- Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):453-8. https://doi.org/10.1007/s00417-012-2038-0.
- Mori R, Tanaka K, Haruyama M, et al. Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2017;238(1-2):17-22. https://doi.org/10.1159/000468950.
- Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):697-704. https://doi.org/10.1007/s00417-012-2090-9.
- Muether PS, Hermann MM, Droge K, et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156(5):989-993 e982. https://doi.org/10.1016/j.ajo.2013.06.020.
- Global Trends in Retina Survey. Ed. by K.A. Rezaei, T.W. Stone. Chicago: American Society of Retina Specialists; 2015.
- Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146-152. https://doi.org/10.1016/j.ophtha.2014.07.041.
- Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. Ophthalmology. 2016;123(1):51-59. https://doi.org/10.1016/j.ophtha.2015.09.018.
- Wykoff CC, Croft DE, Brown DM, et al. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Rela¬ted Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmo¬logy. 2015;122(12):2514-2522. https://doi.org/10.1016/j.ophtha.2015.08.009.
- Ohji M. Two different Treat and Extend dosing regimens of intravitreal aflibercept for wAMD in Japanese patients: 52 weeks results of the ALTAIR study. In: Proceedings of the 17th EURETINA Congress; 2017 Sep 9; Barcelona, Spain.
- Okada AA, Takahashi K. Use of Intravitreal Aflibercept Treat-and-Extend Dosing for Wet Age-Related Macular Degeneration: 52-Week ALTAIR Results. In: Proceedings of the American Aca¬demy of Ophthalmology (AAO) Congress; 2017 Nov 11-14; New Orleans, LA, USA.
- Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158(3):532-536. https://doi.org/10.1016/j.ajo.2014.05.025.
- Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100(11):1494-1498. https://doi.org/10.1136/bjophthalmol-2015-308264.